This poster is published under an
open license. Please read the
disclaimer for further details.
Keywords:
Oncology, Genital / Reproductive system male, Interventional non-vascular, Ultrasound, MR, Diagnostic procedure, Cancer
Authors:
D. Dolgacheva, A. Kaprin, A. Alekseyev, N. Rubtsova, S. O. Stepanov, N. Skreptsova; Moscow/RU
DOI:
10.1594/ecr2015/C-2154
Methods and materials
Subjects were enrolled in a prospective trial assessing MRI/US-fusion guided prostate at the P.A.
Herzen Moscow Oncology Research Institute between May 2014 and September 2014.
During the study period,
a total of 14 MRI/US-fusion guided prostate biopsies were performed,
including 12 patients with repeated biopsies on active surveillance.
Patient demographics and prebiopsy prostate-specific antigen (PSA) level,
number of MP-MRI lesions,
and MP-MRI cancer-suspicion score per lesion were noted.
Patient demographics of the study cohort are shown in Table 1.
The mean age of the patient population was 62 yr and mean prebiopsy PSA level was 6,2 ng/ml.
The mean number of targeted biopsies per patient was 4,2 and the mean total number of biopsies including the standard 12-cores was 16,1.
Table 1.
Patients information
Patient
|
Age
|
PSA
|
Biopsy technique
|
Previous
biopsies
|
1
|
58
|
3,2
|
MRI/US-fusion + TRUS 12-core
|
1
|
2
|
61
|
10,5
|
MRI/US-fusion + TRUS 12-core
|
2
|
3
|
65
|
5,5
|
MRI/US-fusion + TRUS 12-core
|
1
|
4
|
71
|
12,6
|
MRI/US-fusion + TRUS 12-core
|
2
|
5
|
69
|
7,6
|
MRI/US-fusion + TRUS 12-core
|
1
|
6
|
67
|
2,8
|
MRI/US-fusion + TRUS 12-core
|
-
|
7
|
54
|
5,8
|
MRI/US-fusion + TRUS 12-core
|
1
|
8
|
59
|
3,2
|
MRI/US-fusion
|
-
|
9
|
58
|
2,7
|
MRI/US-fusion
|
-
|
10
|
62
|
5,2
|
MRI/US-fusion + TRUS 12-core
|
-
|
11
|
62
|
11,2
|
MRI/US-fusion + TRUS 12-core
|
1
|
12
|
63
|
3,1
|
MRI/US-fusion + TRUS 12-core
|
-
|
13
|
60
|
9,3
|
MRI/US-fusion + TRUS 12-core
|
1
|
14
|
59
|
4,1
|
MRI/US-fusion + TRUS 12-core
|
-
|
All patients initially underwent a diagnostic MP-MRI of the prostate,
including triplanar T2-weighted,
dynamic contrast-enhanced,
diffusion-weighted imaging,
and MR spectroscopy sequences performed on a 2.0T MRI scanner with a 16-channel cardiac surface coil positioned over the pelvis and an endorectal coil.
These diagnostic MP-MRI studies underwent blinded,
centralized radiologic evaluation to identify lesions if present and to assign PCa suspicion scores to each lesion according to PIRADS criteria [2].
A standard 12-core TRUS-guided biopsy in conjunction with a fusion biopsy was performed for 12 patients.
MRI/US-fusion guided biopsy alone was perfomed for 2 patients.
Lesions suspicious for cancer identified on MRI were semiautomatically displayed on the real-time TRUS image.
All target lesions were sampled once in both axial and sagittal planes,
with at least two core biopsies per target.